Clinical Trial Update: Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for empagliflozin in patients with heart failure with reduced ejection fraction has completed enrollment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Morten Schou | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: COMPLETED